Protein Information

General Information of the Protein

Protein ID	PT00980
Protein Name	Aurora kinase A
Secondarily Protein Name	Aurora 2 Aurora/IPL1-related kinase 1 Breast tumor-amplified kinase Ipl1- and aurora-related kinase 1 Serine/threonine-protein kinase 15 Serine/threonine-protein kinase 6 Serine/threonine-protein kinase Ayk1 Serine/threonine-protein kinase aurora-A
Gene Name	AURKA
Secondarily Gene Name	AIK AIRK1 ARK1 AURA AYK1 BTAK IAK1 STK15 STK6
Sequence	MDRSKENCISGPVKATAPVGGPKRVLVTQQFPCQNPLPVNSGQAQRVLCPSNSSQRIPLQAQKLVSSHKPVQNQKQKQLQATSVPHPVSRPLNNTQKSKQPLPSAPENNPEEELASKQKNEESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS Show/Hide
Organism	Homo sapiens, Human
Protein Classification	Enzyme > Kinase > Protein Kinase > Other protein kinase group > Other protein kinase AUR family
Function	Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression (PubMed:26246606, PubMed:12390251, PubMed:18615013, PubMed:11039908, PubMed:17125279, PubMed:17360485). Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis (PubMed:26246606, PubMed:14523000). Required for normal spindle positioning during mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex during metaphase (PubMed:27335426). Required for initial activation of CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2 (PubMed:18056443, PubMed:15128871, PubMed:14702041, PubMed:11551964, PubMed:15147269, PubMed:15987997, PubMed:17604723, PubMed:18615013). Regulates KIF2A tubulin depolymerase activity (PubMed:19351716). Important for microtubule formation and/or stabilization (PubMed:18056443). Required for normal axon formation (PubMed:19812038). Plays a role in microtubule remodeling during neurite extension (PubMed:19668197). Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and destabilizing p53/TP53 (PubMed:14702041). Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia outgrowth (By similarity). Required for cilia disassembly via phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin (PubMed:17604723, PubMed:20643351). Regulates protein levels of the anti-apoptosis protein BIRC5 by suppressing the expression of the SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through the phosphorylation of the transcription factor FOXP1 (PubMed:28218735). Show/Hide
Uniprot ID	Primary ID: O14965 Secondarily ID: E1P5F9 O60445 O75873 Q9BQD6 Q9UPG5 Show/Hide
Ensembl ID	ENSG00000087586
HGNC ID	HGNC:11393
Subcellular Location	Cytoplasm Cytoskeleton Microtubule organizing center Centrosome Cytoplasm Cytoskeleton Spindle pole Cytoplasm Cytoskeleton Microtubule organizing center Centrosome Centriole Cell projection Neuron projection Cell projection Cilium Cytoplasm Cytoskeleton Cilium basal body Basolateral cell membrane

Map of Molecular Bioactivity Related to the Protein

Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity

Table of Molecular Bioactivities Related to the Protein

Cell Line ID: CL000023 , BTI-Tn-5B1-4

Cell Line Info

Compound ID	Compound Name	Compound Formula
CP0430625 Compound Info	4-methyl-N-(3-(2-(6-methyl-5-(2-(thiophen-2-yl)acetamido)-1H-indazol-3-yl)vinyl)phenyl)piperazine-1-carboxamide Show/Hide	C28H30N6O2S	1
1	IC50 = 13 nM Bioactivity Info	TI LI LO TS
CP0470449 Compound Info	N-[6-methyl-3-[(E)-2-phenylethenyl]-1H-indazol-5-yl]-2-thiophen-2-ylacetamide Show/Hide	C22H19N3OS	1
1	IC50 = 17 nM Bioactivity Info	TI LI LO TS
CP0490727 Compound Info	N-[6-methyl-3-[(E)-2-phenylethenyl]-1H-indazol-5-yl]-2-phenylacetamide Show/Hide	C24H21N3O	1
1	IC50 = 19 nM Bioactivity Info	TI LI LO TS
CP0486037 Compound Info	2-phenyl-N-(3-styryl-1H-indazol-5-yl)acetamide Show/Hide	C23H19N3O	1
1	IC50 = 22 nM Bioactivity Info	TI LI LO TS
CP0376394 Compound Info	1-phenyl-N-(3-styryl-1H-indazol-5-yl)methanesulfonamide Show/Hide	C22H19N3O2S	1
1	IC50 = 35 nM Bioactivity Info	TI LI LO TS
CP0477498 Compound Info	N-[3-[(E)-2-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]ethenyl]-1H-indazol-5-yl]-2-thiophen-2-ylacetamide Show/Hide	C27H29N5OS	1
1	IC50 = 35 nM Bioactivity Info	TI LI LO TS
CP0452085 Compound Info	2-(2,5-dimethoxyphenyl)-N-(6-methyl-3-styryl-1H-indazol-5-yl)acetamide Show/Hide	C26H25N3O3	1
1	IC50 = 42 nM Bioactivity Info	TI LI LO TS
CP0376392 Compound Info	N-[6-methyl-3-[(E)-2-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]ethenyl]-1H-indazol-5-yl]-2-thiophen-2-ylacetamide Show/Hide	C28H31N5OS	1
1	IC50 = 79 nM Bioactivity Info	TI LI LO TS
CP0477500 Compound Info	N-[3-[(E)-2-phenylethenyl]-6-pyrrolidin-1-yl-1H-indazol-5-yl]-2-thiophen-2-ylacetamide Show/Hide	C25H24N4OS	1
1	IC50 = 91 nM Bioactivity Info	TI LI LO TS
CP0430626 Compound Info	4-methyl-N-(3-(2-(5-(methylsulfonamido)-6-(pyrrolidin-1-yl)-1H-indazol-3-yl)vinyl)phenyl)piperazine-1-carboxamide Show/Hide	C26H33N7O3S	1
1	IC50 = 140 nM Bioactivity Info	TI LI LO TS
CP0470476 Compound Info	5-(pyridin-4-yl)-6-(pyrrolidin-1-yl)-3-styryl-1H-indazole Show/Hide	C24H22N4	1
1	IC50 = 160 nM Bioactivity Info	TI LI LO TS
CP0477501 Compound Info	6-(pyrrolidin-1-yl)-3-styryl-1H-indazol-5-amine Show/Hide	C19H20N4	1
1	IC50 = 200 nM Bioactivity Info	TI LI LO TS
CP0376393 Compound Info	5-nitro-6-(pyrrolidin-1-yl)-3-styryl-1H-indazole Show/Hide	C19H18N4O2	1
1	IC50 = 240 nM Bioactivity Info	TI LI LO TS
CP0502849 Compound Info	N-[6-methyl-3-(2-phenylethynyl)-2H-indazol-5-yl]-2-thiophen-2-ylacetamide Show/Hide	C22H17N3OS	1
1	IC50 = 240 nM Bioactivity Info	TI LI LO TS
CP0417624 Compound Info	4-methyl-3-(3-((4-methylpiperazin-1-yl)methyl)styryl)-1H-indazole-5-carbonitrile Show/Hide	C23H25N5	1
1	IC50 = 280 nM Bioactivity Info	TI LI LO TS
CP0430624 Compound Info	3-methyl-5-(4-methyl-3-(3-((4-methylpiperazin-1-yl)methyl)styryl)-1H-indazol-5-yl)aniline Show/Hide	C29H33N5	1
1	IC50 = 350 nM Bioactivity Info	TI LI LO TS
CP0494484 Compound Info	3-[(E)-2-phenylethenyl]-N-(pyridin-2-ylmethyl)-6-pyrrolidin-1-yl-1H-indazol-5-amine Show/Hide	C25H25N5	1
1	IC50 = 620 nM Bioactivity Info	TI LI LO TS
CP0470451 Compound Info	2-phenyl-N-(3-(2-phenylcyclopropyl)-1H-indazol-5-yl)acetamide Show/Hide	C24H21N3O	1
1	IC50 = 640 nM Bioactivity Info	TI LI LO TS
CP0417626 Compound Info	2-phenyl-N-[3-(2-phenylethyl)-2H-indazol-5-yl]acetamide Show/Hide	C23H21N3O	1
1	IC50 = 1700 nM Bioactivity Info	TI LI LO TS
CP0470045 Compound Info	N-[4-methyl-3-[(E)-2-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]ethenyl]-1H-indazol-5-yl]-2-thiophen-2-ylacetamide Show/Hide	C28H31N5OS	1
1	IC50 = 1900 nM Bioactivity Info	TI LI LO TS
CP0504238 Compound Info	6-(4-methylpiperazin-1-yl)-N-(pyridin-2-ylmethyl)-3-styryl-1H-indazol-5-amine Show/Hide	C26H28N6	1
1	IC50 > 10000 nM Bioactivity Info	TI LI LO TS

Cell Line ID: CL000067 , HCT 116

Cell Line Info

Cell Line ID: CL000006 , HEK293

Cell Line Info

Cell Line ID: CL000017 , HeLa

Cell Line Info

Cell Line ID: CL000196 , MDA-MB-468

Cell Line Info

Cell Line ID: CL000012 , Sf21

Cell Line Info

Cell Line ID: CL000013 , Sf9

Cell Line Info

Biochemical Assays

Compound ID	Compound Name	Compound Formula
CP0361417 Compound Info	CHEMBL4563026 Show/Hide	C33H34ClFN7O3	1
1	IC50 = 0.06 nM
CP0016524 Compound Info	CHEMBL3600873 Show/Hide	C22H21ClFN3O3S	1
1	IC50 = 0.064 nM
CP0018039 Compound Info	N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Show/Hide	C23H28N8OS	25
1	IC50 = 0.24 nM
2	IC50 = 0.6 nM
3	IC50 = 0.7 nM
4	IC50 = 0.95 nM
5	IC50 = 1.05 nM
6	IC50 = 1.4 nM
7	IC50 = 1.9 nM
8	IC50 = 2.8 nM
9	IC50 = 6 nM
10	IC50 = 15 nM
11	IC50 = 20 nM
12	IC50 = 30 nM
13	IC50 = 31.62 nM
14	IC50 = 127 nM
15	IC50 = 130 nM
16	Kd = 0.3333 nM
17	Kd = 0.645 nM
18	Kd = 3.9 nM
19	Kd = 4 nM
20	Kd = 4.1 nM
21	Kd = 17 nM
22	Ki = 0.37 nM
23	Ki = 0.6 nM
24	Ki = 0.65 nM
25	Ki = 1 nM
CP0004106 Compound Info	(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one Show/Hide	C28H26N4O3	21
1	IC50 = 0.46 nM
2	IC50 = 0.6 nM
3	IC50 = 0.86 nM
4	IC50 = 0.936 nM
5	IC50 <= 1 nM
6	IC50 < 1 nM
7	IC50 = 1.38 nM
8	IC50 = 2 nM
9	IC50 = 2.28 nM
10	IC50 = 2.4 nM
11	IC50 = 3 nM
12	IC50 = 3.67 nM
13	IC50 = 7.63 nM
14	IC50 = 11 nM
15	IC50 = 15 nM
16	IC50 = 18.09 nM
17	IC50 = 22 nM
18	IC50 = 23 nM
19	Kd = 16 nM
20	Kd = 17 nM
21	Kd = 110 nM
CP0674596 Compound Info	(-)-Ethyl 8-Oxo-9-[3-(1H-benzimidazol-2-yloxy)phenyl]-4,5,6,7,8,9-hexahydro-2H-pyrrolo[3,4-b]quinoline-3-carboxylate Show/Hide	C27H24N4O4	1
1	IC50 = 0.6 nM
CP0032546 Compound Info	4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-2-methoxybenzoic acid Show/Hide	C27H20ClFN4O4	3
1	IC50 = 1 nM
2	IC50 = 1.2 nM
3	IC50 = 100 nM
CP0017774 Compound Info	4-[[7-[2,6-bis(fluoranyl)phenyl]-9-chloranyl-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Show/Hide	C25H15ClF2N4O2	5
1	IC50 = 1.5 nM
2	IC50 = 4 nM
3	Kd = 0.3467 nM
4	Kd = 0.9133 nM
5	Kd = 6.5 nM
CP0274623 Compound Info	Bisanilinopyrimidine, 12b Show/Hide	C17H12ClFN8	1
1	IC50 = 2.9 nM
CP0356087 Compound Info	Bisanilinopyrimidine, 12d Show/Hide	C17H12Cl2N8	1
1	IC50 = 3 nM
CP0117152 Compound Info	Bisanilinopyrimidine, 12a Show/Hide	C17H13ClN8	2
1	IC50 = 3.1 nM
2	Kd = 18 nM
CP0037005 Compound Info	2,4-Bisanilinopyrimidine, 10 Show/Hide	C31H31ClFN7O2	1
1	IC50 = 3.4 nM
CP0182104 Compound Info	Bisanilinopyrimidine inhibitor, 2 Show/Hide	C18H14N4O4	4
1	IC50 = 5.1 nM
2	IC50 = 6.1 nM
3	IC50 = 75 nM
4	Kd = 34 nM
CP0267380 Compound Info	Bisanilinopyrimidine, 9l Show/Hide	C19H18ClN5O2	1
1	IC50 = 12.3 nM
CP0025009 Compound Info	Bisanilinopyrimidine, 9m Show/Hide	C17H13ClFN5O	1
1	IC50 = 14.4 nM
CP0075920 Compound Info	4-[[6-chloro-2-(1,3-dimethylpyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-7-yl]oxy]-N-cyclobutylbenzamide Show/Hide	C22H21ClN6O2	1
1	IC50 = 15 nM
CP0365386 Compound Info	Bisanilinopyrimidine, 12c Show/Hide	C17H12ClFN8O	1
1	IC50 = 17.3 nM
CP0147199 Compound Info	Bisanilinopyrimidine, 9c Show/Hide	C20H20ClN5O2	1
1	IC50 = 18 nM
CP0103207 Compound Info	Bisanilinopyrimidine, 9n Show/Hide	C16H13ClFN5O2S	1
1	IC50 = 21.2 nM
CP0238983 Compound Info	Bisanilinopyrimidine, 9j Show/Hide	C20H19ClFN5O	1
1	IC50 = 21.4 nM
CP0318290 Compound Info	Bisanilinopyrimidine, 9k Show/Hide	C21H21ClFN5O	1
1	IC50 = 23.2 nM
CP0051782 Compound Info	1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazole 18 Show/Hide	C28H35N7O2	3
1	IC50 = 27 nM
2	Kd = 1.84 nM
3	Kd = 2.613 nM
CP0267383 Compound Info	Bisanilinopyrimidine, 9h Show/Hide	C20H20ClN5O	1
1	IC50 = 27 nM
CP0301029 Compound Info	Bisanilinopyrimidine, 9a Show/Hide	C23H25ClN6O2	1
1	IC50 = 28.1 nM
CP0284644 Compound Info	Bisanilinopyrimidine, 6p Show/Hide	C17H14ClN5O	1
1	IC50 = 30.2 nM
CP0170069 Compound Info	Bisanilinopyrimidine, 9d Show/Hide	C17H15ClN4O2S	1
1	IC50 = 44.9 nM
CP0204584 Compound Info	4-[[6-chloro-2-(1,3-dimethylpyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-7-yl]oxy]-N-pyridin-3-ylbenzamide Show/Hide	C23H18ClN7O2	1
1	IC50 = 58 nM
CP0270630 Compound Info	4-[[6-chloro-2-(1,3-dimethylpyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-7-yl]oxy]-N-phenylbenzamide Show/Hide	C24H19ClN6O2	1
1	IC50 = 67 nM
CP0296124 Compound Info	4-[[6-chloro-2-(1,3-dimethylpyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-7-yl]oxy]-N-(3-methyl-1,2-oxazol-5-yl)benzamide Show/Hide	C22H18ClN7O3	1
1	IC50 = 71 nM
CP0173802 Compound Info	4-(6,7-Dimethoxy-9H-pyrimido[4,5-b]indol-4-yl)-piperazine-1-carbothioic acid [4-(pyrimidin-2-ylsulfamoyl)-phenyl]-amide Show/Hide	C27H27N9O4S2	2
1	IC50 = 94 nM
2	IC50 = 900 nM
CP0157791 Compound Info	Bisanilinopyrimidine, 9g Show/Hide	C18H15ClN4O3	1
1	IC50 = 116.5 nM
CP0296123 Compound Info	4-[[6-chloro-2-(1,3-dimethylpyrazol-4-yl)-1H-imidazo[4,5-b]pyridin-7-yl]oxy]-N-pyridin-4-ylbenzamide Show/Hide	C23H18ClN7O2	1
1	IC50 = 190 nM
CP0193836 Compound Info	Bisanilinopyrimidine, 9b Show/Hide	C21H23ClN6O	1
1	IC50 = 216 nM
CP0230489 Compound Info	CHEMBL4763626 Show/Hide	C18H16ClN5O5	1
1	IC50 = 222 nM
CP0314266 Compound Info	Bisanilinopyrimidine, 9i Show/Hide	C16H14ClN5O2S	1
1	IC50 = 253 nM
CP0704813 Compound Info	N4-(2-Chlorophenyl)-N2-[6-(1H-benzo[d]imidazol-2(3H)-one)]pyrimidine-2,4-diamine Show/Hide	C17H13ClN6O	1
1	IC50 = 316 nM
CP0036099 Compound Info	1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methyl-phenyl)urea Show/Hide	C21H18FN5O	2
1	IC50 = 760 nM
2	Kd = 1600 nM
CP0634648 Compound Info	N-((R)-Cyclopropyl(pyridin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide Show/Hide	C30H31N5O2	1
1	IC50 = 1300 nM
CP0058395 Compound Info	2-(ethyl(3-(4-(5-(2-(3-fluorophenylamino)-2-oxoethyl)-1H-pyrazol-3-ylamino)quinazolin-7-yloxy)propyl)amino)ethyl dihydrogen phosphate Show/Hide	C26H31FN7O6P	2
1	IC50 = 1400 nM
2	Ki = 1368 nM
CP0018477 Compound Info	4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide Show/Hide	C21H16ClF3N4O3	2
1	IC50 = 3800 nM
2	Kd > 10000 nM
CP0278627 Compound Info	benzyl N-[[4-[3-[[4-(2-pyrrolidin-1-ylethoxy)benzoyl]amino]-1H-pyrazol-5-yl]phenyl]methyl]carbamate Show/Hide	C31H33N5O4	1
1	IC50 > 1000 nM
CP0005066 Compound Info	NR9 Show/Hide	C18H13N3OS2	1
1	IC50 > 10000 nM
CP0030740 Compound Info	1-(5-Tert-Butyl-1,2-Oxazol-3-Yl)-3-(4-{7-[2-(Morpholin-4-Yl)ethoxy]imidazo[2,1-B][1,3]benzothiazol-2-Yl}phenyl)urea Show/Hide	C29H32N6O4S	2
1	IC50 > 10000 nM
2	Kd > 10000 nM
CP0178025 Compound Info	2-[(3R)-3-(3,3-difluoropyrrolidine-1-carbonyl)pyrrolidin-1-yl]-N-[4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]sulfanylphenyl]acetamide Show/Hide	C27H29F2N9O2S	1
1	Kd = 5.8 nM
CP0088050 Compound Info	US9447092, 1 Show/Hide	C22H23Cl2N7	1
1	Kd = 7.5 nM
CP0178029 Compound Info	(3R)-N-cyclopentyl-1-[2-[4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]sulfanylanilino]-2-oxoethyl]pyrrolidine-3-carboxamide Show/Hide	C28H33N9O2S	1
1	Kd = 9.3 nM
CP0016677 Compound Info	N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide Show/Hide	C35H30N4O4	2
1	Kd = 19.29 nM
2	Kd = 120 nM
CP0047080 Compound Info	4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-[2-(6-methylpyridin-3-yl)oxyethylamino]pyridine-3-carbonitrile Show/Hide	C19H21N7O	1
1	Km = 28000 nM

Clinical Information about the Protein

Target 1 ( Aurora kinase A (AURKA) )

Target Type	Clinical trial Target
Disease	6 Target-related Diseases				6
1	Solid tumour/cancer [ICD-11: 2A00-2F9Z]
2	Haematological malignancy [ICD-11: 2B33.Y]
3	Acute myeloid leukaemia [ICD-11: 2A60]
4	Prostate cancer [ICD-11: 2C82.0]
5	Diabetic complication [ICD-11: 5A2Y]
6	Advanced solid tumour [ICD-11: 2A00-2F9Z]
Clinical Trial Drug(s)	14 Clinical Trial Drugs				14
1	AT9283	Drug Info	Phase 3	Solid tumour/cancer
2	MLN8237	Drug Info	Phase 3	Solid tumour/cancer
3	ABT-348	Drug Info	Phase 2	Haematological malignancy
4	ENMD-2076	Drug Info	Phase 2	Acute myeloid leukaemia
5	PHA-739358	Drug Info	Phase 2	Prostate cancer
6	VX-680	Drug Info	Phase 2	Solid tumour/cancer
7	LY3295668	Drug Info	Phase 1/2	Solid tumour/cancer
8	AMG 900	Drug Info	Phase 1	Solid tumour/cancer
9	CYC116	Drug Info	Phase 1	Solid tumour/cancer
10	MK-5108	Drug Info	Phase 1	Solid tumour/cancer
11	MLN8054	Drug Info	Phase 1	Solid tumour/cancer
12	R763	Drug Info	Phase 1	Haematological malignancy
13	Rosiglitazone + metformin	Drug Info	Phase 3	Diabetic complication
14	SNS-314	Drug Info	Phase 1	Solid tumour/cancer
Discontinued Drug(s)	1 Discontinued Drug				1
1	PF-03814735	Drug Info	Discontinued in Phase 1	Advanced solid tumour

Cite

About MolBiC

Correspondence

Prof. Feng ZHU

Prof. Leo, Lianyi Han